Response to comment on "Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: A model-based analysis"

Science Translational Medicine

Volumn 5, Issue 204, 2013, Pages

  Mills, Harriet L ^a   Cohen, Ted ^b,c   Colijn, Caroline ^d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; TUBERCULIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; EARLY DIAGNOSIS; EARLY INTERVENTION; HEALTH CARE NEED; HEALTH CARE POLICY; HUMAN; IMMUNOCOMPROMISED PATIENT; MATHEMATICAL MODEL; NOTE; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SCREENING TEST; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; HUMANS; ISONIAZID; TUBERCULOSIS;

EID: 84884694032     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007442     Document Type: Note

References (10)

1. H. L. Mills, T. Cohen, C. Colijn, Community-wide isoniazid preventive therapy drives drugresistant tuberculosis: A model-based analysis. Sci. Transl. Med. 5, 180ra49 (2013).
2. G. Churchyard, K. L. Fielding, J. J. Lewis, L. Coetzee, E. L. Corbett, P. Godfrey-Faussett, R. Hayes, A. D. Grant; on behalf of the Thibela TB Team, Community-wide isoniazid preventive therapy does not improve tuberculosis control among gold miners: The Thibela TB Study, South Africa. Paper presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5 to 8 March 2012. Abstract 150aLB.
3. T. Oni, R. Burke, R. Tsekela, N. Bangani, R. Seldon, H. P. Gideon, K. Wood, K. A. Wilkinson, T. H. Ottenhoff, R. J. Wilkinson, High prevalence of subclinical tuberculosis in HIV1 infected persons without advanced immunodeficiency: Implications for TB screening. Thorax 66, 669 -673 (2011).
4. C. Akolo, I. Adetifa, S. Shepperd, J. Volmink, Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst. Rev. 20, CD000171 (2010).
5. N. Aït-Khaled, E. Alarcon, K. Bissell, F. Boillot, J. A. Caminero, C. Y. Chiang, P. Clevenbergh, R. Dlodlo, D. A. Enarson, P. Enarson, O. Ferroussier, P. I. Fujiwara, A. D. Harries, E. Heldal, S. G. Hinderaker, S. J. Kim, C. Lienhardt, H. L. Rieder, I. D. Rusen, A. Trébucq, A. Van Deun, N. Wilson, Isoniazid preventive therapy for people living with HIV: Public health challenges and implementation issues. Int. J. Tuberc. Lung Dis. 13, 927-935 (2009).
6. Stop TB Department. World Health Organization 2011 guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Available at: http://whqlibdoc.who.int/publications/2011/9789241500708-eng.pdf (accessed 30 July 2013).
7. M. E. Balcells, S. L. Thomas, P. Godfrey-Faussett, A. D. Grant, Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg. Infect. Dis. 12, 744-751 (2006).
8. C. L. van Halsema, K. L. Fielding, V. N. Chihota, E. C. Russell, J. J. Lewis, G. J. Churchyard, A. D. Grant, Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS 24, 1051-1055 (2010).
9. E. Nardell, G. Churchyard, What is thwarting tuberculosis prevention in high-burden settings? N. Engl. J. Med. 365, 79-81 (2011).
10. S. D. Lawn, R. Wood, Short-course untargeted isoniazid preventive therapy in South Africa: Time to rethink policy? Int. J. Tuberc. Lung Dis. 16, 995-996 (2012).